Instrument Inactif

Gouvernance Plasmatech Biopharmaceuticals Inc Nasdaq

US72754H1095

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

25/06	États-Unis : le prix des nouveaux médicaments a reculé en 2025, porté par la baisse des lancements de thérapies géniques coûteuses	RE
12/06	Abeona Therapeutics Inc. annonce la démission de Michael Amoroso de son poste de membre du conseil d'administration et du comité de nomination et de gouvernance d'entreprise, avec effet au 11 juin 2026	CI

Comité Exécutif: Plasmatech Biopharmaceuticals Inc

Dirigeant

Fonctions occupéesDepuis

Vishwas Seshadri

50 ans

Chief Executive Officer	15/10/2021
Chief Operating Officer	15/10/2021
President	15/10/2021

Brendan OMalley

57 ans

General Counsel	01/01/2019
Corporate Secretary	01/01/2019

James A. Gow

Chief Tech/Sci/R&D Officer

20/10/2025

Joseph Vazzano

42 ans

Comptroller/Controller/Auditor	31/03/2022
Director of Finance/CFO	14/03/2022

Greg Gin

Investor Relations Contact	01/05/2020
Public Communications Contact	-

Carl Denny

General Counsel

01/08/2021

Brian Kevany

Chief Tech/Sci/R&D Officer

01/06/2021

Gianine Esposito

Human Resources Officer

Composition du Conseil d'Administration: Plasmatech Biopharmaceuticals Inc

Administrateur

ComitésDepuis

Faith Charles

65 ans

Audit Committee	03/01/2023
Governance Committee	21/02/2024
Nominating Committee	21/02/2024
Compensation Committee

Donald Wuchterl

56 ans

Audit Committee
Governance Committee	24/05/2021
Nominating Committee	24/05/2021

Bernhardt Zeiher

62 ans

Compensation Committee
Governance Committee	14/03/2024
Nominating Committee	14/03/2024

Mark Alvino

58 ans

Audit Committee Chair
Compensation Committee Chair	25/03/2021

Leila Alland

63 ans

Audit Committee
Compensation Committee	24/05/2021

Keith Goldan

54 ans

Audit Committee Chair

01/04/2026

Vishwas Seshadri

50 ans

Director/Board Member

15/10/2021

Christine Silverstein

43 ans

Director/Board Member	11/03/2020
Independent Dir/Board Member	31/03/2020

Eric Crombez

52 ans

Director/Board Member	12/08/2024
Independent Dir/Board Member	12/08/2024

Anciens Dirigeants et Administrateurs: Plasmatech Biopharmaceuticals Inc

Insider

Fonctions occupées

DepuisJusqu'au

Michael Amoroso

Director/Board Member	19/03/2021	14/10/2021
Chief Executive Officer	19/03/2021	14/10/2021
Chairman	14/10/2021	11/06/2026
Chief Operating Officer	01/11/2020	19/03/2021
Corporate Officer/Principal	09/07/2020	01/11/2020
President	19/03/2021	14/10/2021

Paul Mann

Director/Board Member	17/06/2020	01/01/2023
Independent Dir/Board Member	17/06/2020	01/01/2023

Scott Nogi

Corporate Officer/Principal

01/01/2018

01/07/2022

Alison Hardgrove

Human Resources Officer

01/02/2022

Steve H. Rouhandeh

Director/Board Member	15/04/2020	30/09/2020
Chairman	30/09/2020	14/10/2021

Igor Grachev

Chief Tech/Sci/R&D Officer

01/02/2023

Jodie Gillon

Chief Tech/Sci/R&D Officer	01/01/2019	-
Corporate Officer/Principal	-	01/07/2021

George Migausky

Director/Board Member	17/06/2020	27/09/2020
Independent Dir/Board Member	17/06/2020	27/09/2020

Stephen B. Howell

Director/Board Member	01/01/1996	27/09/2020
Independent Dir/Board Member	07/12/2011	27/09/2020

Stefano Buono

Director/Board Member	10/05/2018	27/09/2020
Independent Dir/Board Member	10/05/2018	27/09/2020

Shawn Tomasello

Director/Board Member	15/04/2020	27/09/2020
Independent Dir/Board Member	15/04/2020	27/09/2020

Brian Pereira

Chairman

15/04/2020

27/09/2020

Joao Siffert

Director/Board Member	11/02/2019	23/09/2020
Chief Executive Officer	26/11/2018	23/09/2020
Chief Tech/Sci/R&D Officer	18/10/2018	23/09/2020

Richard van Dyune

Director/Board Member	10/05/2018	15/04/2020
Independent Dir/Board Member	10/05/2018	15/04/2020

Edward Sturchio

General Counsel	01/07/2019	01/02/2020
Corporate Secretary	01/07/2019	01/02/2020

Timothy Miller

Director/Board Member	15/05/2015	-
Chief Executive Officer	15/05/2015	02/04/2018
Chief Tech/Sci/R&D Officer	29/03/2018	10/01/2020
President	15/05/2015	10/01/2020

Massimiliano Colao

Corporate Officer/Principal

01/01/2017

01/01/2020

Neena Patil

General Counsel	01/09/2018	01/07/2019
Corporate Secretary	01/09/2018	01/07/2019

Victor Paulus

General Counsel

26/06/2019

Edward Carr

Comptroller/Controller/Auditor	26/11/2018	10/08/2021
Director of Finance/CFO	15/04/2020	14/03/2022

F. Carsten Thiel

Director/Board Member	10/05/2018	26/11/2018
Chief Executive Officer	02/04/2018	26/11/2018

Jeffrey Davis

Director/Board Member	01/03/2006	15/05/2017
Chief Executive Officer	26/12/2007	19/09/2014
Chief Operating Officer	19/01/2015	30/09/2018
Director of Finance/CFO	01/03/2006	-
President	01/03/2006	19/09/2014
Corporate Secretary	01/03/2006	-
Treasurer	01/03/2006	-

Kristina Maximenko

Human Resources Officer

01/06/2018

James Bircher

Chief Tech/Sci/R&D Officer	01/01/2018	-
Corporate Officer/Principal	01/01/2018	-

Harrison Wehner

Director of Finance/CFO

01/06/2014

01/12/2017

Astrid Paneda Rodriguez

Chief Tech/Sci/R&D Officer

01/10/2017

Juan Ruiz

Chief Tech/Sci/R&D Officer	25/07/2017	18/10/2018
Corporate Officer/Principal	18/10/2018	-

Mark J. Ahn

Director/Board Member	01/09/2006	09/01/2017
Independent Dir/Board Member	01/09/2006	09/01/2017

Kaye Spratt

General Counsel

01/11/2015

Scott Schorer

Chief Executive Officer

19/09/2014

15/05/2015

Todd Wider

Director/Board Member	07/05/2015	-
Independent Dir/Board Member	07/05/2015	-

Stephen B. Thompson

Comptroller/Controller/Auditor	01/01/1990	31/10/2013
Director of Finance/CFO	01/01/1990	31/10/2013
Corporate Secretary	01/01/1990	31/10/2013
Treasurer	01/01/1990	31/10/2013
Comptroller/Controller/Auditor	01/01/2015	26/11/2018
Director of Finance/CFO	01/01/2015	31/12/2018
Corporate Secretary	01/01/2015	18/10/2018
Treasurer	01/01/2015	31/12/2018

Esteban Cvitkovic

Director/Board Member	01/02/2007	24/05/2012
Corporate Officer/Principal	01/02/2007	24/05/2012

Anthony Mottola

Corporate Officer/Principal

24/03/2011

David Luci

Director/Board Member

01/02/2009

01/01/2010

Frank A. Jacobucci

Sales & Marketing

20/01/2010

Arash Hanifi

Chief Operating Officer	01/01/2004	01/08/2009
Founder	01/01/2004	01/08/2009

Rosemary Mazanet

Director/Board Member

01/05/2005

21/05/2008

Stephen R. Seiler

President

08/01/2007

19/12/2007

Herbert H. McDade

Director/Board Member

01/05/2007

Max E. Link

Director/Board Member

01/05/2007

Stuart M. Duty

Director/Board Member

08/02/2007

Phillip S. Wise

Corporate Officer/Principal

01/06/2006

John V. St. John

Chief Tech/Sci/R&D Officer

01/03/2000

01/10/2005

Daniel G. Moro

Corporate Officer/Principal

01/09/2000

01/10/2005

Kerry P. Gray

President

01/06/1993

10/05/2005

John J. Meakem

Director/Board Member

01/01/2001

David P. Nowotnik

Corporate Officer/Principal

01/11/1998

Glynn Wilson

Chief Tech/Sci/R&D Officer

01/01/1997

01/01/1998

W. Eric Bowditch

Corporate Officer/Principal

01/01/1996

01/01/1998

J. Michael Flinn

Chairman

01/01/1983

Kate Imhoff

General Counsel

Magdalena Tyrpien

Investor Relations Contact	-	03/05/2016
Corporate Officer/Principal	-	-

Richard Berenson Stone

Director/Board Member

Eric J. Dadey

Corporate Officer/Principal

Christine A. Berni

Investor Relations Contact

24/03/2011

Andre’a Lucca

Public Communications Contact

Scott Santiamo

Public Communications Contact

01/01/2018

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	15
Femme	4

Dont comité exécutif

Homme	7
Femme	1

Dont Administrateurs

Homme	7
Femme	2

Abeona Therapeutics Inc. est une société biopharmaceutique en phase commerciale qui développe des thérapies cellulaires et géniques destinées au traitement de maladies graves. Le produit ZEVASKYN (prademagène zamikeracel) de la société est une thérapie génique à base de cellules autologues destinée au traitement des plaies chez les adultes et les enfants atteints d’épidermolyse bulleuse dystrophique récessive. Son site de fabrication cGMP entièrement intégré dédié aux thérapies cellulaires et géniques, situé à Cleveland, dans l'Ohio, sert de site de production pour la fabrication commerciale de ZEVASKYN. Son portefeuille de développement comprend des thérapies géniques à base de virus adéno-associés (AAV) destinées aux maladies ophtalmiques présentant des besoins médicaux non satisfaits importants. Ses capsides AAV font actuellement l'objet d'évaluations visant à améliorer les profils de tropisme pour diverses maladies dévastatrices. Ses programmes en cours de développement comprennent l'ABO-504 (maladie de Stargardt), l'ABO-503 (rétinoschisis lié au chromosome X), l'ABO-505 (atrophie optique autosomique dominante), UX111 (syndrome de Sanfilippo de type A (MPS IIIA)), TSHA-102 (syndrome de Rett) et TSHA-118 (maladie de Batten infantile (maladie CLN1)).

Employés

Secteur

Produits pharmaceutiques

Plus d'informations sur la société